MEDP
NASDAQMedpace Holdings Inc.
News · 26 weeks51+25%
2026-03-012026-08-23
Mix2590d
- Insider16(64%)
- SEC Filings5(20%)
- Earnings2(8%)
- Analyst2(8%)
Latest news
25 items- INSIDERPresident & CEO Troendle August J. sold $9,969,094 worth of shares (15,978 units at $623.93), decreasing direct ownership by 3% to 545,217 units (SEC Form 4)4 - Medpace Holdings, Inc. (0001668397) (Issuer)
- INSIDERCFO & Treasurer Brady Kevin M. exercised 3,400 shares at a strike of $138.87 and sold $2,125,816 worth of shares (3,400 units at $625.24) (SEC Form 4)4 - Medpace Holdings, Inc. (0001668397) (Issuer)
- INSIDERPresident & CEO Troendle August J. sold $26,281,390 worth of shares (42,783 units at $614.30), decreasing direct ownership by 7% to 561,195 units (SEC Form 4)4 - Medpace Holdings, Inc. (0001668397) (Issuer)
- INSIDERDirector Carley Brian T sold $3,043,150 worth of shares (5,000 units at $608.63), decreasing direct ownership by 15% to 27,825 units (SEC Form 4)4 - Medpace Holdings, Inc. (0001668397) (Issuer)
- INSIDERDirector Davenport Fred B Jr exercised 7,583 shares at a strike of $116.08 and sold $4,414,590 worth of shares (7,283 units at $606.15), increasing direct ownership by 9% to 3,798 units (SEC Form 4)4 - Medpace Holdings, Inc. (0001668397) (Issuer)
- SECSEC Form 144 filed by Medpace Holdings Inc.144 - Medpace Holdings, Inc. (0001668397) (Subject)
- INSIDERPresident & CEO Troendle August J. sold $7,111,969 worth of shares (11,824 units at $601.49), decreasing direct ownership by 2% to 603,978 units (SEC Form 4)4 - Medpace Holdings, Inc. (0001668397) (Issuer)
- INSIDERDirector Mccarthy Cornelius P. Iii sold $690,122 worth of shares (1,140 units at $605.37), decreasing direct ownership by 8% to 12,275 units (SEC Form 4)4 - Medpace Holdings, Inc. (0001668397) (Issuer)
- INSIDERPresident & CEO Troendle August J. sold $13,984,854 worth of shares (23,144 units at $604.25), decreasing direct ownership by 4% to 615,802 units (SEC Form 4)4 - Medpace Holdings, Inc. (0001668397) (Issuer)
- INSIDERDirector Mccarthy Cornelius P. Iii exercised 3,858 shares at a strike of $84.36 and sold $465,131 worth of shares (795 units at $585.07), increasing direct ownership by 30% to 13,415 units (SEC Form 4)4 - Medpace Holdings, Inc. (0001668397) (Issuer)
- INSIDERPresident & CEO Troendle August J. sold $4,346,004 worth of shares (7,238 units at $600.44), decreasing direct ownership by 1% to 638,946 units (SEC Form 4)4 - Medpace Holdings, Inc. (0001668397) (Issuer)
- INSIDERExec. VP, Operations Burwig Susan E sold $4,500,000 worth of shares (7,500 units at $600.00), decreasing direct ownership by 11% to 62,984 units (SEC Form 4)4 - Medpace Holdings, Inc. (0001668397) (Issuer)
- SECSEC Form 144 filed by Medpace Holdings Inc.144 - Medpace Holdings, Inc. (0001668397) (Subject)
- SECSEC Form 10-Q filed by Medpace Holdings Inc.10-Q - Medpace Holdings, Inc. (0001668397) (Filer)
- SECMedpace Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Medpace Holdings, Inc. (0001668397) (Filer)
- PRMedpace Holdings, Inc. Reports Second Quarter 2026 ResultsRevenue of $707.3 million in the second quarter of 2026 increased 17.2% from revenue of $603.3 million for the comparable prior-year period, representing a backlog conversion rate of 24.1%. Net new business awards were $795.7 million in the second quarter of 2026, representing an increase of 28.2% from net new business awards of $620.5 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.13x. Second quarter of 2026 GAAP net income was $121.4 million, or $4.25 per diluted share, versus GAAP net income of $90.3 million, or $3.10 per diluted share, for the comparable prior-year period. Net income margin was 17.2% and 15.0% for the second quarter
- ANALYSTMedpace downgraded by Robert W. Baird with a new price targetRobert W. Baird downgraded Medpace from Outperform to Neutral and set a new price target of $547.00
- ANALYSTMedpace downgraded by Jefferies with a new price targetJefferies downgraded Medpace from Buy to Hold and set a new price target of $515.00
- INSIDERDirector Mccarthy Cornelius P. Iii converted options into 28 shares, increasing direct ownership by 0.27% to 10,352 units (SEC Form 4)4 - Medpace Holdings, Inc. (0001668397) (Issuer)
- INSIDERDirector Kraft Robert O. converted options into 33 shares, increasing direct ownership by 4% to 955 units (SEC Form 4)4 - Medpace Holdings, Inc. (0001668397) (Issuer)
- INSIDERDirector Carley Brian T converted options into 36 shares, increasing direct ownership by 0.11% to 32,825 units (SEC Form 4)4 - Medpace Holdings, Inc. (0001668397) (Issuer)
- PRMedpace Holdings, Inc. to Report Second Quarter 2026 Financial Results on July 22, 2026Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its second quarter 2026 financial results after the market close on Wednesday, July 22, 2026. The Company will host a conference call the following morning, Thursday, July 23, 2026, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be u
- INSIDERNew insider Hansman Brad W. claimed ownership of 697 shares (SEC Form 3)3 - Medpace Holdings, Inc. (0001668397) (Issuer)
- SECSEC Form 8-K filed by Medpace Holdings Inc.8-K - Medpace Holdings, Inc. (0001668397) (Filer)
- INSIDERGeneral Counsel & Corp. Secy. Ewald Stephen P exercised 16,349 shares at a strike of $138.87 and sold $7,357,050 worth of shares (16,349 units at $450.00) (SEC Form 4)4 - Medpace Holdings, Inc. (0001668397) (Issuer)
MEDP FAQ
7 questionsWhat does Medpace Holdings Inc. do?
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and...Where does MEDP stock trade?
Medpace Holdings Inc. (MEDP) is listed on NASDAQ.What sector and industry is MEDP in?
Medpace Holdings Inc. operates in the Health Care sector, Biotechnology: Commercial Physical & Biological Resarch industry.When did Medpace Holdings Inc. go public?
Medpace Holdings Inc. (MEDP) completed its IPO in 2016.What are analysts saying about MEDP?
Medpace Holdings Inc. has had 8 recent analyst actions on file. The most recent action was from Robert W. Baird: Neutral on 2026-07-08.What companies are similar to MEDP?
Notable peers in the same industry include IQV (IQVIA Holdings Inc.), INCY (Incyte Corp.), PPD (PPD, Inc.), CRL (Charles River Laboratories International Inc.), ICLR (ICON plc). Compare MEDP side-by-side with any of them on Quantisnow.How can I track MEDP on Quantisnow?
Quantisnow aggregates Medpace Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MEDP to receive live email and push alerts on every new disclosure.